S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
3 Free Stock Picks per Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
3 Free Stock Picks per Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
3 Free Stock Picks per Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
3 Free Stock Picks per Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
3 Free Stock Picks per Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
3 Free Stock Picks per Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
3 Free Stock Picks per Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
3 Free Stock Picks per Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
NASDAQ:EMBC

Embecta (EMBC) Stock Forecast, Price & News

$26.90
-0.32 (-1.18%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$26.62
$27.82
50-Day Range
$26.85
$31.07
52-Week Range
$22.30
$36.64
Volume
288,500 shs
Average Volume
639,314 shs
Market Capitalization
$1.54 billion
P/E Ratio
16.60
Dividend Yield
2.23%
Price Target
$26.50

Embecta MarketRank™ Forecast

Analyst Rating
Reduce
1.33 Rating Score
Upside/​Downside
1.5% Downside
$26.50 Price Target
Short Interest
Bearish
5.74% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.38mentions of Embecta in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-10.38%
From $2.60 to $2.33 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.39 out of 5 stars

Medical Sector

954th out of 1,010 stocks

Surgical & Medical Instruments Industry

95th out of 104 stocks


EMBC stock logo

About Embecta (NASDAQ:EMBC) Stock

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

Receive EMBC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter.

EMBC Stock News Headlines

Embecta (NASDAQ:EMBC) Releases FY 2023 Earnings Guidance
Embecta (EMBC) vs. The Competition Head to Head Contrast
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Critical Contrast: Embecta (EMBC) and Its Rivals
Embecta (EMBC) and The Competition Financial Analysis
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
embecta to Participate in Investor Conferences
8-K: Embecta Corp.
BTIG Keeps Their Hold Rating on Embecta Corporation (EMBC)
Embecta: Q2 Earnings Insights
Embecta (EMBC) Set to Announce Quarterly Earnings on Friday
Embecta Corp. (NASDAQ:EMBC) Short Interest Update
See More Headlines
Receive EMBC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter.

EMBC Company Calendar

Ex-Dividend for 6/13 Dividend
5/25/2023
Ex-Dividend for 6/13 Dividend
5/25/2023
Today
5/29/2023
Dividend Payable
6/13/2023
Dividend Payable
6/13/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EMBC
Fax
N/A
Employees
2,029
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.50
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
-1.5%
Consensus Rating
Reduce
Rating Score (0-4)
1.33
Research Coverage
3 Analysts

Profitability

Net Income
$223.60 million
Pretax Margin
11.33%

Debt

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$5.49 per share
Book Value
($15.41) per share

Miscellaneous

Free Float
57,168,000
Market Cap
$1.54 billion
Optionable
Optionable
Beta
N/A

Key Executives

  • Mr. Devdatt Kurdikar (Age 53)
    Pres, CEO & Director
    Comp: $1.19M
  • Mr. Jacob P. Elguicze (Age 49)
    Sr. VP & CFO
    Comp: $519.14k
  • Mr. Jeffrey Z. Mann (Age 49)
    Sr. VP, Gen. Counsel, Head of Corp. Devel. & Corp. Sec.
    Comp: $294.04k
  • Mr. Ajay Kumar (Age 51)
    Sr. VP & Chief HR Officer
    Comp: $616.87k
  • Mr. Shaun Curtis (Age 52)
    Sr. VP of Global Manufacturing & Supply Chain
    Comp: $501.99k
  • Mr. Brian R. Capone (Age 47)
    VP, Chief Accounting Officer & Corp. Controller
  • Ms. Colleen Riley (Age 57)
    Sr. VP & Chief Technology Officer
  • Ms. Ginny Blocki
    Sr. VP of Global Marketing & Product Management
  • Mr. Tom Blount (Age 48)
    Sr. VP & Pres of North America
  • Mr. Slobodan Radumilo (Age 51)
    Sr. VP & Pres of International













EMBC Stock - Frequently Asked Questions

Should I buy or sell Embecta stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Embecta in the last year. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "sell" EMBC shares.
View EMBC analyst ratings
or view top-rated stocks.

What is Embecta's stock price forecast for 2023?

3 equities research analysts have issued 1 year price objectives for Embecta's shares. Their EMBC share price forecasts range from $25.00 to $28.00. On average, they predict the company's stock price to reach $26.50 in the next twelve months. This suggests that the stock has a possible downside of 1.5%.
View analysts price targets for EMBC
or view top-rated stocks among Wall Street analysts.

How have EMBC shares performed in 2023?

Embecta's stock was trading at $25.29 on January 1st, 2023. Since then, EMBC stock has increased by 6.4% and is now trading at $26.90.
View the best growth stocks for 2023 here
.

How often does Embecta pay dividends? What is the dividend yield for Embecta?

Embecta announced a quarterly dividend on Friday, May 12th. Shareholders of record on Monday, May 29th will be paid a dividend of $0.15 per share on Tuesday, June 13th. This represents a $0.60 annualized dividend and a yield of 2.23%. The ex-dividend date of this dividend is Thursday, May 25th.
Read our dividend analysis for EMBC
.

Is Embecta a good dividend stock?

Embecta (NASDAQ:EMBC) pays an annual dividend of $0.60 per share and currently has a dividend yield of 2.23%. The dividend payout ratio is 37.04%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, EMBC will have a dividend payout ratio of 25.75% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for EMBC.

What guidance has Embecta issued on next quarter's earnings?

Embecta updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided EPS guidance of $2.50-$2.60 for the period, compared to the consensus earnings per share estimate of $2.09. The company issued revenue guidance of $1.10 billion-$1.11 billion, compared to the consensus revenue estimate of $1.10 billion.

What is Embecta's stock symbol?

Embecta trades on the NASDAQ under the ticker symbol "EMBC."

Who are Embecta's major shareholders?

Embecta's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.67%), American Century Companies Inc. (8.08%), FMR LLC (7.88%), Yacktman Asset Management LP (4.53%), State Street Corp (3.96%) and Geode Capital Management LLC (1.96%).
View institutional ownership trends
.

How do I buy shares of Embecta?

Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Embecta's stock price today?

One share of EMBC stock can currently be purchased for approximately $26.90.

How much money does Embecta make?

Embecta (NASDAQ:EMBC) has a market capitalization of $1.54 billion and generates $1.13 billion in revenue each year. The company earns $223.60 million in net income (profit) each year or $1.62 on an earnings per share basis.

How many employees does Embecta have?

The company employs 2,029 workers across the globe.

How can I contact Embecta?

The official website for the company is www.embecta.com. The company can be reached via phone at 201-847-6880 or via email at investor.relations@embecta.com.

This page (NASDAQ:EMBC) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -